The load-bearing event of the quarter is unambiguous: on August 10, 2026 AbCellera released positive top-line data from the Phase 2 trial of ABCL635 in moderate-to-severe vasomotor symptoms (VMS) due to menopause, and the equity repriced accordingly. The Phase 2 readout showed an 83% reduction in moderate-to-severe VMS frequency at week 4 against a 33% placebo reduction (a 50 percentage-point placebo-adjusted difference), a 58% reduction in VMS severity against a 12% placebo reduction, and a clean safety profile with no severe adverse events, no Grade 3+ events, and no liver signal, against a backdrop where the two approved competing non-hormonal therapies, fezolinetant (Veozah, Astellas) and elinzanetant (Lynkuet, Bayer), have each had a clinically meaningful share of their labels shaped by hepatotoxicity concerns. The Phase 2 data support advancing ABCL635 to late-stage development in VMS due to both menopause and oncology treatments, and management framed the asset as having best-in-class potential, a market estimated at $6B+ for non-hormonal treatments, with the immediate trading setup shaped by the fact that the equity entered the readout having fallen roughly 76% from its 52-week high, making the print one of the more asymmetric clinical-stage setups of the year.
The financial picture for the quarter is the natural counterpart to that clinical print. Q2 2026 revenue of $4.05M was down 76% year over year because Q2 2025 carried a one-time $10.4M licensing and royalty payment from Eli Lilly that did not recur, and the $4.05M base is the new run-rate from which ABCL635-driven optionality is being priced. Q2 2026 net loss of $(55.4M), or $(0.18) per share, was 60% wider than Q2 2025 net loss of $(34.7M), and H1 2026 net loss reached $(98.6M) against H1 2025 net loss of $(80.3M), with the year-on-year compression driven by the absence of the Lilly receipt and by the ramp of clinical-stage and IND-enabling program investment rather than by any operating cost miss. The cash story, however, is the counterpoint: H1 2026 net cash used in operations was $(7.6M), versus $(44.0M) in H1 2025, because $44.1M of deferred revenue (the Jazz and Vertex upfronts) was added to the balance sheet, and the company ended the quarter with $540.1M of cash and marketable securities, plus $110M of undrawn non-dilutive government funding, for $675M of total available liquidity, a sum that, combined with the $187M net proceeds of the August 12, 2026 underwritten offering, funds the pipeline well beyond the next three years at the current burn rate.
The question the next six months are set up to answer is whether ABCL635's Phase 2 profile survives the regulatory and dose-selection steps the company has flagged for late 2026 and 2027, and whether the partnership engine that produced $112M of upfront cash from Jazz and Vertex in the second quarter can keep replenishing the balance sheet on the same capital-efficient terms. The bull case, in our view, is that ABCL635 enters a Phase 3 in 2027 with a clean liver signal, a once-monthly subcutaneous dosing schedule, and a long-acting profile that materially improves on the daily oral standard, and that the partnership book continues to monetize non-core TCE and multispecific programs at a pace that preserves the $675M-plus liquidity profile even as the clinical-stage burn steps up. The bear case is that a longer-term liver signal emerges in the 12-week follow-up, that a competitor with greater capital depth (Astellas, Bayer) accelerates a follow-on program that compresses the differentiated positioning, or that a Phase 3 failure to confirm the placebo-adjusted difference at week 12 turns the readout into a one-quarter trade. The data points that test this in the next two quarters are the Q4 2026 Phase 1 readout of ABCL575 in atopic dermatitis, the 12-week ABCL635 follow-up supporting dose selection, and the regulatory interaction the company has guided for late-stage development planning.